Back HIV/AIDS

HIV / AIDS

IDWeek 2014: HIV Attachment Inhibitor BMS-663068 Works Well Across Patient Subgroups

An experimental attachment inhibitor that binds to the surface of the HIV envelope and prevents it from attaching to and entering CD4 T-cells demonstrated good virological response rates and tolerability regardless of age, sex, or race/ethnicity, according to research presented at IDWeek 2014, now underway in Philadelphia.

alt

IDWeek 2014: Social Network Strategies Encourage HIV Testing

Face-to-face social networking among peers is a more effective and proactive way to identify people with HIV infection than standard counseling, testing, and referral methods, according to study findings presented yesterday at the IDWeek 2014 conference in Philadelphia. In an analysis of 45 sites in Wisconsin, researchers found that social networking strategies identified a higher proportion of people who tested HIV positive than traditional methods.

alt

Second Potentially Cured Baby Has HIV Relapse Soon After Stopping Treatment

An Italian child who started antiretroviral treatment soon after birth and had undetectable plasma viral load, no apparent HIV DNA, and tested HIV antibody negative nevertheless experienced viral rebound shortly after a treatment interruption, once again disappointing hopes for a cure, researchers reported in the October 4 edition of The Lancet.

alt

IDWeek 2014: HIV Care Cascade at Kaiser Permanente Varies by Sex and Age

Though there has been improving performance of healthcare delivery at each point of the HIV care cascade, from linkage to care through viral suppression, "success varies significantly by age and gender, even in an integrated care system with equal access to care,” Michael Horberg of the Mid-Atlantic Permanente Research Institute reported yesterday at IDWeek 2014 in Philadelphia.

alt

HIVMA Issues Guidelines for Managing Chronic Kidney Disease in People with HIV

The HIV Medical Association (HIVMA) of the Infectious Diseases Society of America (IDSA) has released updated recommendations for HIV positive people with chronic kidney disease. The guidelines, published in the September 17 issue of Clinical Infectious Diseases, state that antiretroviral therapy (ART) is beneficial for such patients, but they should avoid tenofovir (Viread, also in the Truvada, Atripla, Complera, and Stribild coformulations), which can cause kidney impairment.

alt

Researchers Capture Images of HIV Spike Proteins that Allow Cell Entry

A team of researchers from the National Institutes of Health, Yale University, and Weill Cornell Medical College has found a way to visualize the activity of "spikes" on the surface of the HIV-1 envelope that change structure to enable the virus to enter host cells, according to reports published simultaneously in the October 8 editions of Science and Nature.

alt

UNAIDS: "Fast Track" Strategy Could Help End AIDS Epidemic by 2030

A rapid acceleration of HIV prevention and treatment efforts over the next 5 years directed at people most at risk in high prevalence areas could help turn the tide in the AIDS epidemic, according to participants at a recent high-level meeting during the 69th United Nations General Assembly. If fully implemented, this approach could potentially prevent 18 million new HIV infections and 11 million deaths by 2030, as well as reducing future costs.

alt